Multiple myeloma: open trials in Canada

49 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT07831122
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Trial Treatment · Phase 1 · Canadian Myeloma Research Group
Cross Cancer Institute, Edmonton · QEII Health Sciences Centre, Halifax · London Health Sciences Centre, London · McGill University Health Centre (MUHC), Montreal · Hospital Maisonneuve-Rosemont, Montreal · The Ottawa Hospital - General Hospital, Ottawa · UHN Princess Margaret Cancer Centre, Toronto
Registry updated 2026-09-21
NCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Celgene
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · QEII Health Sciences Centre, Victoria General Site, Halifax · Princess Margaret Cancer Centre, Toronto · Vancouver
Registry updated 2026-09-02
NCT05272826
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Trial Treatment · Phase 2 · Canadian Myeloma Research Group
Cross Cancer Institute, Edmonton · QEII Health Science Centre, Halifax · London Health Sciences Centre, London · Hôpital Maisonneuve-Rosemont, Montreal · McGill University Health Centre, Montreal · NL Health Services, St. John's · Princess Margaret Hospital, Toronto
Registry updated 2026-08-31
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · QEII Health Sciences Centre, Victoria General Site, Halifax · Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton · CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal · Jewish General Hospital, Montreal · Saskatoon Cancer Center, Saskatoon · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-08-24
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Trial Treatment · Phase 3 · Pfizer
The Moncton Hospital, Moncton · Jewish General Hospital, Montreal · l'Hôpital du Sacré-Cœur-de-Montréal, Montreal
Registry updated 2026-08-24
NCT07764978
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Trial Treatment · Phase 3 · AstraZeneca
Calgary · Halifax · Montreal · Ottawa · Sherbrooke · Vancouver
Registry updated 2026-08-14
NCT07728188
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · AbbVie
London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 282149, London · Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 281705, Montreal · British Columbia Cancer Agency Vancouver Centre /ID# 282147, Victoria
Registry updated 2026-07-27
NCT07094048
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Trial Treatment · Phase 4 · CHU de Quebec-Universite Laval
Santé Québec Chaudière-Appalaches, Lévis · Centre Intégré de Cancérologie, Québec
Registry updated 2026-07-22
NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-07-16
NCT02343042
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Trial Treatment · Phase 1/2 · Karyopharm Therapeutics Inc
Tom Baker Cancer Center/Alberta Health Services, Calgary · Cross Cancer Institute (University of Alberta), Edmonton · Queen Elizabeth II Health Sciences Center, Halifax · Royal Victoria Hospital / McGill University, Montreal · Maisonneuve-Rosemont Hospital, Montreal · Memorial Hospital of Newfoundland, St. John's · Princess Margaret Cancer Centre, Toronto · Vancouver General Hospital, Vancouver · Cancer Care Manitoba, Winnipeg
Registry updated 2026-07-15
NCT05650632
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · AbbVie
Juravinski Cancer Centre /ID# 252053, Hamilton · Ottawa Hospital Research Institute /ID# 252151, Ottawa
Registry updated 2026-07-13
NCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 4 · Pfizer
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · McGill University Health Centre, Montreal
Registry updated 2026-07-01
NCT07456605
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
Trial Treatment · Phase 1 · University Health Network, Toronto
University Health Network - Princess Margaret Cancer Centre, Toronto
Registry updated 2026-06-12
NCT06896916
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · AbbVie
Jewish General Hospital /ID# 267574, Montreal · University Health Network_Princess Margaret Cancer Centre /ID# 275636, Toronto
Registry updated 2026-05-12
NCT05645510
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Research · University of Alberta
Edith Pituskin, Edmonton
Registry updated 2026-05-11
NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Trial Treatment · Phase 3 · GlaxoSmithKline
Saint John
Registry updated 2026-04-22
NCT03297606
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Trial Treatment · Phase 2 · Canadian Cancer Trials Group
Cross Cancer Institute, Edmonton · BCCA - Kelowna, Kelowna · Kingston Health Sciences Centre, Kingston · London Health Sciences Centre Research Inc., London · The Jewish General Hospital, Montreal · Ottawa Hospital Research Institute, Ottawa · Allan Blair Cancer Centre, Regina · Saskatoon Cancer Centre, Saskatoon · University Health Network, Toronto · BCCA - Vancouver, Vancouver
Registry updated 2026-03-27
NCT06630806
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Trial Treatment · Phase 1 · Sanofi
Montreal · Sherbrooke · Vancouver
Registry updated 2026-03-25
NCT04988555
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Trial Treatment · Phase 1/2 · Sumitomo Pharma America, Inc.
Tom Baker Cancer Center, Calgary · University of Alberta, Edmonton
Registry updated 2026-03-24
NCT06251076
Plan Development for Giving Teclistamab in the Outpatient Setting
Trial Treatment · Phase 4 · University Health Network, Toronto
Princess Margaret Cancer Centre, Toronto
Registry updated 2025-12-10
NCT06485076
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Trial Treatment · University Health Network, Toronto
Princess Margaret Cancer Centre, Toronto
Registry updated 2025-12-03
NCT05372354
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Bristol-Myers Squibb
Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary · University of Alberta - Cross Cancer Institute, Edmonton · University Health Network UHN - Princess Margaret Hospital PMH, Toronto
Registry updated 2025-09-05
NCT05530096
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Research · Sir Mortimer B. Davis - Jewish General Hospital
Jewish General Hospital, Montreal
Registry updated 2025-04-03
NCT06817759
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer
Trial Treatment · Ciusss de L'Est de l'Île de Montréal
Centre de Recherche de l'Hôpital Maissonneuve-Rosemont, Montreal
Registry updated 2025-02-10

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error